Overview

Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate the efficacy of choline alphoscerate on improving symptoms related to depression, anxiety, and subjective memory complaints compared to placebo in patients with Major Depressive Disorder(MDD) accompanied with subjective cognitive decline, who are over the age of 60.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Choline
Criteria
Inclusion Criteria:

1. Age ≥ 60 years

2. Diagnosed as MDD under the criteria of Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) and confirmed with MINI-Depression

3. HAM-D ≥ 14

4. MMSE ≥ 20

5. Who had continuous subjective memory complaints more than 6 months before the period
of screening

6. Who had taking antidepressants longer than 1 month in the period of screening

Exclusion Criteria:

1. Diagnosed as schizophrenia, bipolar disorder, PTSD, OCD or other significant mental
disorder under the criteria of DSM-5 (only the participants who had depressive
disorder, sleep disorder, and the anxiety disorder are allowed to be included)

2. Who have medically unstable disease (only the participants, who have diabetes mellitus
or hypertension under control with stable medication for 3 months could be included)

3. Diagnosed as dementia or mild cognitive impairment

4. Participants who are already taking choline alfoscerate within 6 months of period

5. Participants who have been taking medication of antipsychotics (including quetiapine),
mood stabilizer, cognitive enhancer including donepezil, rivastigamine, galantamine,
and memantine within 1months.

6. Participants who had previous history of liver disease or renal disease

7. Participants who had allergic reaction to choline alfoscerate

8. Other specific condition, which could be inappropriate for the trial inclusion, under
the judgement of the principal investigator